Poseida Therapeutics, Inc. (CIK: 0001661460) EDGAR, Information, Filings... CompaniesBIO.Com

Poseida Therapeutics, Inc.

Mailing address
9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Phone
858-779-3100
State location
California
State of incorporation
N/A
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Poseida Therapeutics, Inc. (CIK: 0001661460) is an American company incorporated in the state of California. Head office is located at 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, California, 92121. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Poseida Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Lloyd Marcea Bland	0001389208	Jun-15-2023	director
Collins Cynthia	0001405692	Jun-15-2023	director
Schmid John P.	0001478916	Jun-15-2023	director
BAUM CHARLES M	0001579824	Jun-15-2023	director
Corning Luke	0001836654	Jun-15-2023	director
Amado Rafael	0001662119	Apr-13-2023	director
Yarema Kristin	0001803794	Apr-11-2023	officer: President, Cell Therapy
Warner Brent	0001910914	Feb-21-2022	officer: President, Gene Therapy
LEONHARDT HARRY J	0001286102	Sep-15-2020	officer: GC & Chief Compliance Officer
NOVARTIS PHARMA AG	0001030617	Jul-09-2020	10 percent owner
NOVARTIS AG	0001114448	Jul-09-2020	10 percent owner
Gergen Mark J	0001373110	Jul-09-2020	director, officer: President and CBO
Hirsch David	0001619884	Jul-09-2020	director
MACKEY CATHERINE J	0001645330	Jul-09-2020	director
Malin Corp plc	0001673063	Jul-09-2020	10 percent owner
Murphy Sean	0001685042	Jul-09-2020	director, 10 percent owner
Malin Life Sciences Holdings Ltd	0001685138	Jul-09-2020	10 percent owner
Ostertag Eric	0001765987	Jul-09-2020	director, 10 percent owner, officer: Chief Executive Officer
Mylet Johanna	0001765988	Jul-09-2020	officer: Senior Vice President, Finance
Spear Matthew A.	0001766302	Jul-09-2020	officer: Chief Medical Officer
Ingalls Kerry D.	0001816804	Jul-09-2020	officer: Chief Operating Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Poseida Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
EFFECT	Document	Acc-no: 9999999995-24-002530 (33 Act) Size: 1 KB	Aug-14-2024	333-281248 241210466
S-3	Document	Registration statement for specified transactions by certain issuers Acc-no: 0001193125-24-193971 (33 Act) Size: 1426 KB	Aug-05-2024	333-281248 241175307
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-090747 (34 Act) Size: 8505 KB	Aug-05-2024	001-39376 241174855
8-K	Document	Current report filing Acc-no: 0000950170-24-090732 (34 Act) Size: 324 KB	Aug-05-2024	001-39376 241174722
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074875 ( Act) Size: 6 KB	Jun-18-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074873 ( Act) Size: 7 KB	Jun-18-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074872 ( Act) Size: 6 KB	Jun-18-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074865 ( Act) Size: 6 KB	Jun-18-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074864 ( Act) Size: 7 KB	Jun-18-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074862 ( Act) Size: 6 KB	Jun-18-2024
8-K	Document	Current report filing Acc-no: 0000950170-24-074860 (34 Act) Size: 169 KB	Jun-18-2024	001-39376 241051863
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001086364-24-007797 (34 Act) Size: 12 KB	Jun-07-2024	005-91606 241028548
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-059551 (34 Act) Size: 7237 KB	May-14-2024	001-39376 24944446
8-K	Document	Current report filing Acc-no: 0000950170-24-059522 (34 Act) Size: 293 KB	May-14-2024	001-39376 24944265
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-058649 (34 Act) Size: 95 KB	May-08-2024	005-91606 24925725
EFFECT	Document	Acc-no: 9999999995-24-001373 (33 Act) Size: 1 KB	May-03-2024	333-278559 24915372
CORRESP	Document	A correspondence can be sent as a document with another submission type or can be sent as a separate submission. Acc-no: 0001193125-24-127440 ( Act) Size: 6 KB	May-01-2024
8-K	Document	Current report filing Acc-no: 0001193125-24-126509 (34 Act) Size: 192 KB	May-01-2024	001-39376 24900431
ARS	Document	Annual report to security holders Acc-no: 0000950170-24-048315 (34 Act) Size: 10204 KB	Apr-25-2024	001-39376 24876395
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0000950170-24-048303 (34 Act) Size: 1853 KB	Apr-25-2024	001-39376 24876331

Recent 20 filings. View all Poseida Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Poseida Therapeutics, Inc. overview
Poseida Therapeutics, Inc. job
Poseida Therapeutics, Inc. stock
Poseida Therapeutics, Inc. ownership
Poseida Therapeutics, Inc. CEO
Poseida Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.